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One hundred eleven clinical Trichophyton rubrum isolates were tested against 7 antifungal agents. The geometric mean MICs of
all isolates were, in increasing order: terbinafine, 0.03 mg/liter; voriconazole, 0.05 mg/liter; posaconazole, 0.11 mg/liter; isavu-
conazole, 0.13 mg/liter; itraconazole, 0.26 mg/liter; griseofulvin, 1.65 mg/liter; and fluconazole, 2.12 mg/liter.
Dermatophytosis caused by Trichophyton rubrum is the mostcommon cutaneous fungal infection worldwide (1), which
represents the cause of between 80% and 90% of all chronic and
recurrent infections (2). These infections establish an important
public health problem because of the prolonged treatment re-
quired for the disease, because of the frequent recurrence of infec-
tion, and because they are generally considered difficult tomanage
(3). Reliable in vitro susceptibility testing would therefore be use-
ful for selecting the most suitable antifungal treatment. For many
years, griseofulvin was the only approved systemic antidermato-
phytic agent (4). However, nowadays, many potent antifungal
agents are available for the treatment of dermatophytosis, such as
allylamines and triazoles, which have more potent activity and
fewer side effects (5–19). The expansion of information on in vitro
susceptibility testing of dermatophytes to new antifungal agents
will help in the selection and development of antifungal drug reg-
imens.
The aim of the current study was to compare in vitro the activ-
ities of three newer triazoles, voriconazole, posaconazole, and isa-
vuconazole, and four established antifungal agents against T.
rubrum infection. One hundred eleven clinical isolates of T.
rubrum were collected from seven dermatology clinics in Shang-
hai, China. Morphological identifications were confirmed by se-
quence-based analysis of the internal transcribed spacer of the
rRNAgene region. The in vitro activities of seven antifungal agents
were determined according to the CLSI reference guideline
M38-A2 (20), with minor modifications. Two reference strains,
Trichophytonmentagrophytes (strain ATCCMYA-4439) andCan-
dida parapsilosis (strain ATCC 22019), were included as quality
controls. Student’s t test with the statistical SPSS package (version
9.0) was used, and P values of0.05 were considered statistically
significant.
Table 1 lists the MIC ranges, geometric mean (GM) MICs,
MIC50s, and MIC90s of seven antifungal agents against 111 T.
rubrum strains. Terbinafine, voriconazole, posaconazole, isavu-
conazole, itraconazole, and griseofulvin had low MICs against all
tested strains, whereas fluconazole did not show inhibitory effects.
Similar results have been achieved in other studies (Table 2); how-
ever, limited data are available for the newer triazoles isavucona-
zole and posaconazole.
Terbinafine was one of the most effective antifungal agents
against T. rubrum among the 7 fungal agents tested, and our find-
ings confirm those of previous studies (5–19) (Table 2).
We compared the in vitro activities of the 3 newer triazoles
isavuconazole, posaconazole, and voriconazole with that of itra-
conazole. Three newer triazoles offered good in vitro activity
against T. rubrum (Table 1). All isolates were far more susceptible
to the 3 newer triazoles than to itraconazole (Table 1) and com-
parable to those reported by other studies (7, 9, 10, 14, 17, 18).
Isavuconazole is a novel broad-spectrum triazole agent and has
the samemechanism of action as the other triazoles. Several stud-
ies have supported its efficacy in invasive Candida species, Cryp-
tococcus neoformans, Aspergillus species, and Mucorales isolates
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TABLE 1 Geometric mean MICs, MIC ranges, MIC50s, and MIC90s
obtained by susceptibility testing of antifungal agents against 111 T.
rubrum clinical isolates
Drug
MIC/MEC (mg/liter)
Range 50% 90% Geometric mean
Griseofulvin 1–4 2 2 1.65
Fluconazole 0.125–64 2 64 2.12
Itraconazole 0.031–16 0.5 2 0.26
Voriconazole 0.031–16 0.031 0.125 0.05
Posaconazole 0.016–1 0.125 0.5 0.11
Isavuconazole 0.031–4 0.06 0.125 0.13
Terbinafine 0.008–0.06 0.031 0.06 0.03
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(5–19, 21). However, the antifungal susceptibility profile of der-
matophytes remains poorly examined. Ghannoum and Isham re-
ported that isavuconazole had shown potent in vitro activity
against dermatophytes (22) and was more active than other tria-
zoles tested (itraconazole and voriconazole), but it had a higher
MIC than that of terbinafine; however, against T. rubrum isolates
with high MICs to terbinafine, the isavuconazole MICs remained
low (0.06 mg/liter for all tested isolates) (23). In our study, the
MICs of isavuconazole (GM, 0.13mg/liter;MIC90, 0.125mg/liter)
were similar to those of posaconazole (GM, 0.11 mg/liter; MIC90,
0.5 mg/liter) and voriconazole (GM, 0.05 mg/liter; MIC90, 0.125
mg/liter); the differencewaswithin 1 log2-dilution step,whichwas
much lower than those of itraconazole (GM, 0.26 mg/liter; MIC90
2 mg/liter) for the majority of the T. rubrum isolates tested.
Posaconazole showed activity similar to that described by
Gupta, Kohli, andBatra (14), who reported posaconazole to be the
most active compound, with an MIC90 of 1.0 mg/liter; the
MIC90 was 0.5mg/liter in our study. Similar data were reported by
Singh, Zaman, and Gupta (10); however, the MIC was greater
than that reported by us and Gupta, Kohli, and Batra (14). This
variation may be a result of the different methods used (Table 2).
The potent activity of posaconazole against Trichophyton viola-
ceum (T. rubrum complex) has been reported by us as well (24).
The excellent activity of voriconazole against T. rubrum has
been observed by B. Fernández-Torres et al. (17) and A. J. Car-
rillo-Muñoz et al. (9), with sample sets of 144 and 139 isolates,
respectively (GM for both, 0.06 mg/liter). Our findings with 111
isolates have confirmed this good activity (GM, 0.05 mg/liter).
There were, however, some discrepancies; in two of the previous
reports, voriconazole appeared to be less active than itraconazole
(7, 18). This could be attributed, at least partially, to the different
methodology employed and the lack of standardized protocols.
Our previous study (24) revealed that voriconazole had potent
activity against T. violaceum.
For itraconazole, significant variations are shown in the pub-
lished literature (Table 2). Overall, the geometric mean MIC of
itraconazole for half of the isolates was 0.1 mg/liter, and the
highest GM was 0.59 mg/liter (16), followed by 0.42 mg/liter (8).
Our results showed good in vitro activity of itraconazole againstT.
rubrum (GM, 0.26mg/liter); however, itraconazole was less active
than the three new triazoles tested.
Griseofulvin was the first-line antifungal agent for the treat-
ment of dermatophytoses for many years, but today, it is not
widely used (4), due to griseofulvin-resistant isolates of dermato-
phytes and the existence of strains with elevated MICs to griseof-
ulvin (6, 25–27). With our results, the MICs of griseofulvin for T.
rubrum were in agreement with those reported by Adimi et al. (7)
and Perea et al. (18). Griseofulvin was less active than the rest of
the agents tested except for fluconazole against T. rubrum. Never-
theless, all strains were more susceptible to griseofulvin than to
fluconazole (Table 1).
Among the studies reported in Table 2, fluconazole also was
effective againstT. rubrum, except in a study byAdimi et al. (7). Of
all the agents tested in the current study, fluconazole showed the
lowest activity, which was consistent with previous studies (9, 10,
16); although T. rubrum is not susceptible to fluconazole, it is
recommended for the management of some dermatophytoses
(28–30).
In conclusion, terbinafine, voriconazole, posaconazole, and
isavuconazole were shown in vitro to be the most potent antifun-T
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gal agents against theT. rubrum isolates investigated. These results
might help clinicians to develop appropriate therapies for treating
dermatophytosis caused by T. rubrum. However, further clinical
investigations must be conducted in order to develop interpretive
breakpoints.
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